Hugel Inc., a leading South Korea–based global medical aesthetics company, has announced the appointment of Carrie Strom as President and Global Chief Executive Officer, effective October 13, 2025. Strom, a seasoned executive with over 25 years in the pharmaceutical and aesthetics industry, previously served as Global President of Allergan Aesthetics, an AbbVie company, where she managed a $5 billion global portfolio including Botox Cosmetic and Juvéderm.
In her new role at Hugel, Strom will lead the company’s global expansion strategy, focusing on reinforcing its position as a market leader in botulinum toxin and dermal fillers. Her leadership is expected to accelerate Hugel’s transformation into a global aesthetics powerhouse, strengthening its footprint across the U.S., China, Europe, and beyond.
Strom’s appointment aligns with Hugel’s strategic vision to enhance its global presence and innovation in the medical aesthetics sector. The company has rapidly expanded its global footprint, now marketing its botulinum toxin products in 69 countries and its dermal fillers in 53 countries. As the market-leading botulinum toxin brand in South Korea, Hugel is the only South Korean company to have regulatory approvals in the world’s three largest markets: the U.S., China, and Europe.
Strom’s extensive experience and proven track record in the aesthetics industry position her to drive Hugel’s growth and innovation on a global scale. Her leadership is anticipated to propel Hugel towards achieving its strategic goals and further solidify its standing in the competitive global aesthetics market.
